CD1-HM119F-100μg / 询价
CD1-HM119F-500μg / 询价
CD1-HM119F-500μgx2 / 询价
- 客服电话
- 技术支持
FITC-Compatible Human CD19 Protein
FITC-Compatible Human CD19 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Pro20-Lys291.[Accession | P15391-1]
The protein has a predicted MW of 60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Tris-Bis PAGE result.
Excitation Wavelength: 490 nm
Emission Wavelength: 520 nm
Less than 1 EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
FITC-Compatible Human CD19 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of FITC-Compatible Human CD19 is greater than 95% as determined by SEC-HPLC.
Use 100 μl FITC-Compatible Human CD19 (10 μg/ml) to detect the positive rate of 1×106 anti-CD19 CAR cells and FITC-labeled irrelevant protein (100 μl, 10 μg/ml) was served as a negative control.
CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.
CD19; B4; CVID3; Leu-12; MGC12802
(1) Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019 May;94(S1):S42-S49. doi: 10.1002/ajh.25445. Epub 2019 Mar 6. PMID: 30784102.
